$0.93
5.51% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US29446K1060
Symbol
EQ
Sector
Industry

Equillium, Inc. Stock price

$0.93
+0.20 26.87% 1M
-1.33 59.03% 6M
+0.20 28.08% YTD
+0.13 15.75% 1Y
-5.09 84.62% 3Y
-3.02 76.56% 5Y
-13.07 93.39% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.05 5.51%
ISIN
US29446K1060
Symbol
EQ
Sector
Industry

Key metrics

Market capitalization $32.80m
Enterprise Value $110.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.00
P/S ratio (TTM) P/S ratio 0.77
P/B ratio (TTM) P/B ratio 1.46
Revenue growth (TTM) Revenue growth 26.25%
Revenue (TTM) Revenue $42.62m
EBIT (operating result TTM) EBIT $-9.71m
Free Cash Flow (TTM) Free Cash Flow $-15.77m
Cash position $33.30m
EPS (TTM) EPS $-0.24
P/E forward negative
P/S forward 0.70
EV/Sales forward 0.00
Short interest 0.80%
Show more

Is Equillium, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Equillium, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Equillium, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Equillium, Inc. forecast:

Buy
100%

Financial data from Equillium, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
43 43
26% 26%
100%
- Direct Costs 0.13 0.13
8% 8%
0%
42 42
26% 26%
100%
- Selling and Administrative Expenses 13 13
18% 18%
31%
- Research and Development Expense 39 39
7% 7%
91%
-9.58 -9.58
49% 49%
-22%
- Depreciation and Amortization 0.13 0.13
8% 8%
0%
EBIT (Operating Income) EBIT -9.71 -9.71
49% 49%
-23%
Net Profit -8.32 -8.32
54% 54%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Equillium, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Equillium, Inc. Stock News

Neutral
Business Wire
about 2 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 m...
Neutral
Business Wire
3 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, ac...
Neutral
Business Wire
3 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on May 31, 2024, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 sh...
More Equillium, Inc. News

Company Profile

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO Bruce Steel
Employees 44
Founded 2017
Website www.equilliumbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today